Shares of Illumina, Inc. (ILMN) advanced to $161.58. The price had gained 0.92% or 1.48 points intraday. The latest trading session witnessed $73.14 million in upticks and $80.24 million in downticks, resulting in net money flow of (-7.1) million. The up/down ratio for the day stood at 0.91. On a weekly scale, the price has seen a change of 0.37%. From the trading data available, it was disclosed that a block trade of negative money flow worth $(-4.79) million occurred during the day. $0 million in uptick and $4.79 million in downtick were the highlight of the block transaction which had an up/down ratio of 0.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Illumina, Inc. rose by 0.32% in the last five trading days and 26.19% for the last 4 weeks. Illumina, Inc. is up 18.69% in the last 3-month period. Year-to-Date the stock performance stands at 26.19%. Illumina, Inc. (NASDAQ:ILMN) rose 0.92% or 1.48 points on Wednesday and made its way into the gainers of the day. After trading began at $158 the stock was seen hitting $163.8 as a peak level and $156.5 as the lowest level. The stock ended up at $161.58. The daily volume was measured at 1,790,253 shares. The 52-week high of the share price is $186.88 and the 52-week low is $119.37. The company has a market cap of $23,736 million.
Company has reported several Insider transactions to the SEC, on Jan 31, 2017, Omead Ostadan (EVP Ops, Products, Strategy) sold 259 shares at 160.90 per share price.On Jan 13, 2017, A Blaine Bowman (director) sold 3,000 shares at 162.97 per share price.On Jan 6, 2017, Daniel Bradbury (director) sold 600 shares at 134.74 per share price.
Illumina Last issued its quarterly earnings results on Jan 31, 2017. The company reported $0.85 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $0.83. The company had revenue of $619.00 million for the quarter, compared to analysts expectations of $614.41 million. The companys revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.81 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by UBS on Feb 1, 2017 to Buy, Raises Price Target to $ 185 from a previous price target of $180 .Illumina was Initiated by Deutsche Bank on Jan 18, 2017 to Hold, Price Target of the shares are set at $160.Illumina was Upgraded by BofA/Merrill to Buy on Jan 10, 2017. Illumina was Upgraded by CL King to Buy on Jan 6, 2017. Illumina was Reiterated by Morgan Stanley on Dec 7, 2016 to Underweight, Lowers Price Target to $ 100 from a previous price target of $115 .
Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The companys tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.